Search results for "ABO"

showing 10 items of 13628 documents

A 2013 European survey of clinical practice patterns in the management of Graves' disease

2014

SummaryObjective Management of Graves' disease (GD) in Europe was published in 1987. Aim of this survey was to provide an update on clinical practice in Europe, and to compare it with a 2011 American survey. Design Members of the European Thyroid Association (ETA) were asked to participate in a survey on management of GD, using the same questionnaire of a recent American survey. Results A total of 147 ETA members participated. In addition to serum TSH and free T4 assays, most respondents would request TSH-receptor autoantibody (TRAb) measurement (85·6%) and thyroid ultrasound (70·6%) to confirm aetiology, while isotopic studies were selected by 37·7%. Antithyroid drug (ATD) therapy was the …

medicine.medical_specialtyExacerbationEndocrinology Diabetes and MetabolismGraves' diseaseThyrotropin030209 endocrinology & metabolismTrabDisease03 medical and health sciences0302 clinical medicineEndocrinologyAntithyroid AgentsPregnancySurveys and QuestionnairesInternal medicinemedicineHumansPractice Patterns Physicians'AutoantibodiesPregnancyMethimazolebusiness.industryThyroidReceptors Thyrotropinmedicine.diseaseGraves DiseaseEuropePregnancy ComplicationsThyroxineEndocrinologymedicine.anatomical_structurePropylthiouracil030220 oncology & carcinogenesisNorth AmericaEtiologyFemalePropylthiouracilbusinessmedicine.drugClinical Endocrinology
researchProduct

Eye Muscle Antibodies in Endocrine Exophthalmos

1989

Serum samples were obtained from 65 patients with endocrine exophthalmos class I-V. In 33/65 patients who were treated either with prednisone or with ciclosporin, blood was sampled before, during and after therapy. Antibodies against eye muscle were determined during the course of immunosuppressive therapy in order to have an objective parameter of the therapeutic effect. To ascertain the specificity of the reaction both eye and abdominal muscles were used as antigens in an ELISA system. Both IgG and IgM antibodies were detected. In 45/65 patients (71%) eye muscle antibodies were positive before starting therapy. Antibodies were mostly detected in patients with active disease. Patients with…

medicine.medical_specialtyExophthalmosEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBiochemistrySerologyEndocrinologyAntigenInternal medicinemedicinebiologybusiness.industryBiochemistry (medical)ThyroidRadioimmunoassayGeneral MedicineEndocrinologymedicine.anatomical_structureImmunologybiology.proteinThyroglobulinThyroid functionmedicine.symptomAntibodybusinessHormone and Metabolic Research
researchProduct

2018

Objective: Acromegalic patients display a distinct neuropsychological profile and suffer from chronic physical complaints. We aimed to investigate in more detail these aspects in acromegalic patients, dependent on influencing factors like disease activity, age, sex, chronic medication, surgery, pituitary radiation, pituitary insufficiency and comorbidities. Design: Cross sectional, multicentric. Methods: 129 patients (M/W 65/64, 58.3 ± 12.7 years, 53/76 with active/controlled disease). Acromegalic patients completed the following inventories: NEO-FFI, IIP-D, and the Giessen Complaints List (GBB-24), after written informed consent. Age, sex, IGF-1 concentrations, comorbidities, treatment mod…

medicine.medical_specialtyExtraversion and introversionbusiness.industryEndocrinology Diabetes and MetabolismNeuropsychology030209 endocrinology & metabolismDiseasemedicine.diseaseComorbidityNeuroticism03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineAcromegalymedicinePermissiveBig Five personality traitsbusinessFrontiers in Endocrinology
researchProduct

Improvement of asymmetric thyroid eye disease with teprotumumab

2021

PurposeTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients.MethodsIn this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, prop…

medicine.medical_specialtyEye disease030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlacebo03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicineBlocking antibodyDiplopiamedicineExophthalmosHumansDifferential impactDiplopiabusiness.industryThyroidmedicine.diseaseeye diseasesSensory SystemsGraves OphthalmopathyClinical trialOphthalmologyPooled analysismedicine.anatomical_structure030221 ophthalmology & optometrymedicine.symptombusinessBritish Journal of Ophthalmology
researchProduct

Role of exercise-induced hepatokines in metabolic disorders.

2019

International audience; The health-promoting effects of physical activity to prevent and treat metabolic disorders are numerous. However, the underlying molecular mechanisms are not yet completely deciphered. In recent years, studies have referred to the liver as an endocrine organ, since it releases specific proteins called hepatokines. Some of these hepatokines are involved in whole body metabolic homeostasis and are theorized to participate in the development of metabolic disease. In this regard, the present review describes the role of Fibroblast Growth Factor 21, Fetuin-A, Angiopoietin-like protein 4, and Follistatin in metabolic disease and their production in response to acute exerci…

medicine.medical_specialtyFGF21PhysiologyEndocrinology Diabetes and MetabolismPhysical activity030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineMetabolic DiseasesRegular exerciseNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineEndocrine systemMedicineAnimalsHumansObesityMetabolic diseaseBeneficial effectsExercise030304 developmental biology0303 health sciencesbiologybusiness.industry[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthEndocrinologyDiabetes Mellitus Type 2Liverbiology.proteinCytokinesInsulin ResistanceWhole bodybusinessFollistatinAmerican journal of physiology. Endocrinology and metabolism
researchProduct

Farber disease (acid ceramidase deficiency) epidemiology: literature review and patient cohort data indicate moderate and attenuated phenotypes are l…

2017

medicine.medical_specialtyFarber diseasePathologybusiness.industryEndocrinology Diabetes and Metabolismmedicine.diseaseBiochemistryPhenotypeAcid Ceramidase Deficiency03 medical and health sciences0302 clinical medicineEndocrinology030220 oncology & carcinogenesisInternal medicineCohortEpidemiologyGeneticsMedicinebusinessMolecular Biology030217 neurology & neurosurgeryMedical literatureMolecular Genetics and Metabolism
researchProduct

Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.

2007

In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered with simvastatin in the treatment of primary mixed hyperlipidaemia, we conducted a study that compared increasing dosages of these drugs in subgroups of men and women belonging to a clinical sample of outpatients. This was an open study carried out in patients with primary mixed hyperlipidaemia (lipoprotein phenotype IIb) who needed a combined therapeutic approach because of their poor response to a single-drug regimen with an HMG-CoA reductase inhibitor (simvastatin). Thus, a fibrate (fenofibrate) was added to the therapy. The study lasted 12 months. Forty-five patients (mean age: 58.9 ± 11.3 years…

medicine.medical_specialtyFenofibrateDosemedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineFibratePharmacologyGastroenterologyDiscontinuationRegimenTolerabilitySimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Adverse effectbusinessmedicine.drugClinical drug investigation
researchProduct

Postnatal weight change is influenced by mother-newborn pair leptin levels

2000

We investigated serum leptin levels in 103 mother-newborn-pairs; Cord leptin was significantly higher than mother's leptin (5.7 ± 5.5 vs. 22.1 ± 19.9 ng/ml; p <0.001). Cord leptin was significantly higher in females than males (6.9 ± 6.3 vs. 3.9 ± 3.6 ng/ml respectively; p <0.001), and correlated with maternal leptin (r = 0.24; p = 0.001), gestational age (r = 0.54; p <0.001), and birth weight (r = 0.56; p <0.001). Neonatal leptin at the 4(th) day significantly correlated with percent weight loss in the first four days of life. These observations shed light on the origin of cord leptin and on the role of leptin in postnatal weight loss. (C) 2000 Elsevier Science Inc.

medicine.medical_specialtyFetusNutrition and DieteticsCordEndocrinology Diabetes and MetabolismBirth weightLeptindigestive oral and skin physiologyWeight changePeptide hormoneBiologyCord leptin levelEndocrinologyEndocrinologyNeonatal growth factorWeight lossCord bloodInternal medicinemedicinePostnatal weight loss.medicine.symptomhormones hormone substitutes and hormone antagonistsNutrition Research
researchProduct

ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture

2015

Changes in bone density and bone markers suggest that pregnancy is associated with deterioration of bone mass in the mother. The metabolism of calcium resets to allow for the needs imposed by the building of the fetal skeleton. The fetus contributes to the process through the output of regulators from the placenta. Understanding of the whole process is limited, but some changes are unambiguous. There is an increase in the circulating levels of vitamin D, but its functional impact is unclear. Fetal parathyroid hormone (PTH) and PTH-related peptide (PTHrp) play an indirect role through support of a calcium gradient that creates hypercalcemia in the fetus. Placental GH, which increases up to t…

medicine.medical_specialtyFetusPregnancyBone densitybusiness.industryEndocrinology Diabetes and MetabolismOsteoporosisParathyroid hormoneGeneral Medicinemedicine.diseaseBone resorptionBone remodelingEndocrinologyEndocrinologyOsteoprotegerinInternal medicinemedicinebusinessEuropean Journal of Endocrinology
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct